Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

1. HIMS targets low testosterone market, estimated at 20 million U.S. men. 2. Expansion includes exclusive testosterone product launch in 2026 with Marius Pharmaceuticals. 3. Pricing options vary; treatments start at $199/month for testosterone therapy. 4. Acquisition of Trybe Labs enhances HIMS's at-home testing capabilities. 5. Stock rose 5.99% following the announcement amid strategic growth initiatives.